SEC Form 4 · accession 0001144204-15-021061
Harvard Apparatus Regenerative Technology, Inc. · HRGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John F Kennedy
Director
Period of report
May 29, 2014
Accepted (ET)
Apr 2, 2015 · 7:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001563665
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 29, 2014 | M | 139 | $4.75 | A | 2,724 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F2,F3 | $4.75 | May 29, 2014 | M | 139 | D | — | Jun 4, 2014 | Common Stock, par value $0.01 per share | 139 | 0 | D |
Explanation of responses
- F1Following the exercise of the stock options on May 29, 2014, this amount included (a) a deferred stock award of 309 restricted stock units which vest in equal installments on June 1, 2014 and June 1, 2015; (b) a deferred stock award of 326 restricted stock units which fully vested on May 31, 2014; and (c) 2,089 shares of common stock held by the Reporting Person. As of April 2, 2015, this amount includes (a) a deferred stock award of 154 restricted stock units which vest on June 1, 2015; and (b) 2,570 shares of common stock held by the Reporting Person.
- F2Represents exercise of stock options acquired by the Reporting Person in connection with the adjustment to the existing options and restricted stock units held by the Reporting Person and issued by Harvard Bioscience, Inc. These issuances by the Issuer to the Reporting Person were required in connection with the spin-off of the Issuer by Harvard Bioscience. The share amounts and exercise prices of these options and restricted stock units issued by the Issuer were set in a manner to ensure the intrinsic value held by the Reporting Person pertaining to the existing awards issued by Harvard Bioscience was maintained immediately following the spin-off. In addition to these grants by the Issuer, to maintain such intrinsic value, adjustments to the existing equity awards issued by Harvard Bioscience were also made in favor of the Reporting Person.
- F3The option shares vested in three equal installments on June 4, 2005, 2006 and 2007.
Remarks
This form has been signed under power of attorney.